Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Evidence-based indicators for the measurement of quality of primary care using health insurance claims data in Switzerland: results of a pragmatic consensus process.

Blozik E, Reich O, Rapold R, Scherer M; Swiss Quality Indicator for Primary Care (SQIPRICA) Working Group.

BMC Health Serv Res. 2018 Sep 27;18(1):743. doi: 10.1186/s12913-018-3477-z.

2.

Outcomes and costs of Ranibizumab and Aflibercept treatment in a health-service research context.

Schmid MK, Reich O, Blozik E, Faes L, Bodmer NS, Locher S, Thiel MA, Rapold R, Kuhn M, Bachmann LM.

BMC Ophthalmol. 2018 Feb 27;18(1):64. doi: 10.1186/s12886-018-0731-4.

3.

Injections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from Switzerland.

Reich O, Schmid MK, Rapold R, Bachmann LM, Blozik E.

BMC Ophthalmol. 2017 Dec 4;17(1):234. doi: 10.1186/s12886-017-0617-x.

4.

Epidemiology and costs of multiple sclerosis in Switzerland: an analysis of health-care claims data, 2011-2015.

Blozik E, Rapold R, Eichler K, Reich O.

Neuropsychiatr Dis Treat. 2017 Nov 1;13:2737-2745. doi: 10.2147/NDT.S143180. eCollection 2017.

5.

The Patient Enrolled in a Managed Care Insurance Plan or the Physician Being Part of a Network: What Drives the Efficiency Gain?

Reich O, Rapold R, Blozik E.

Praxis (Bern 1994). 2017;106(7):351-358. doi: 10.1024/1661-8157/a002640. German. No abstract available.

PMID:
28357898
6.

One-year adherence to oral antihyperglycemic medication and risk prediction of patient outcomes for adults with diabetes mellitus: An observational study.

Huber CA, Rapold R, Brüngger B, Reich O, Rosemann T.

Medicine (Baltimore). 2016 Jun;95(26):e3994. doi: 10.1097/MD.0000000000003994.

7.

A set of four simple performance measures reflecting adherence to guidelines predicts hospitalization: a claims-based cohort study of patients with diabetes.

Huber CA, Brändle M, Rapold R, Reich O, Rosemann T.

Patient Prefer Adherence. 2016 Mar 1;10:223-31. doi: 10.2147/PPA.S99895. eCollection 2016.

8.

Days spent in acute care hospitals at the end of life of cancer patients in four Swiss cantons: a retrospective database study (SAKK 89/09).

Matter-Walstra KW, Achermann R, Rapold R, Klingbiel D, Bordoni A, Dehler S, Konzelmann I, Mousavi M, Clough-Gorr KM, Szucs T, Schwenkglenks M, Pestalozzi BC.

Eur J Cancer Care (Engl). 2017 Jul;26(4). doi: 10.1111/ecc.12453. Epub 2016 Feb 9.

PMID:
26856977
9.

Prescription of potentially inappropriate medication in older persons in Switzerland: does the dispensing channel make a difference?

Blozik E, Rapold R, Reich O.

Risk Manag Healthc Policy. 2015 Apr 24;8:73-80. doi: 10.2147/RMHP.S78179. eCollection 2015.

10.

Anti-VEGF treatment patterns and associated health care costs in Switzerland: findings using real-world claims data.

Reich O, Bachmann LM, Faes L, Böhni SC, Bittner M, Howell JP, Thiel MA, Rapold R, Schmid MK.

Risk Manag Healthc Policy. 2015 Apr 21;8:55-62. doi: 10.2147/RMHP.S80536. eCollection 2015.

11.

Estimating the prevalence of comorbid conditions and their effect on health care costs in patients with diabetes mellitus in Switzerland.

Huber CA, Diem P, Schwenkglenks M, Rapold R, Reich O.

Diabetes Metab Syndr Obes. 2014 Oct 1;7:455-65. doi: 10.2147/DMSO.S69520. eCollection 2014.

12.

Cancer-related therapies at the end of life in hospitalized cancer patients from four Swiss cantons: SAKK 89/09.

Matter-Walstra KW, Achermann R, Rapold R, Klingbiel D, Bordoni A, Dehler S, Jundt G, Konzelmann I, Clough-Gorr K, Szucs T, Pestalozzi BC, Schwenkglenks M.

Oncology. 2015;88(1):18-27. doi: 10.1159/000367629. Epub 2014 Sep 26.

13.

Potentially inappropriate medication use in older patients in Swiss managed care plans: prevalence, determinants and association with hospitalization.

Reich O, Rosemann T, Rapold R, Blozik E, Senn O.

PLoS One. 2014 Aug 19;9(8):e105425. doi: 10.1371/journal.pone.0105425. eCollection 2014.

14.

Epidemiology and costs of diabetes mellitus in Switzerland: an analysis of health care claims data, 2006 and 2011.

Huber CA, Schwenkglenks M, Rapold R, Reich O.

BMC Endocr Disord. 2014 Jun 3;14:44. doi: 10.1186/1472-6823-14-44.

15.

Delivery of health care at the end of life in cancer patients of four swiss cantons: a retrospective database study (SAKK 89/09).

Matter-Walstra KW, Achermann R, Rapold R, Klingbiel D, Bordoni A, Dehler S, Jundt G, Konzelmann I, Clough-Gorr KM, Szucs TD, Schwenkglenks M, Pestalozzi BC.

BMC Cancer. 2014 May 1;14:306. doi: 10.1186/1471-2407-14-306.

16.

The relationship between functional health literacy and the use of the health system by diabetics in Switzerland.

Franzen J, Mantwill S, Rapold R, Schulz PJ.

Eur J Public Health. 2014 Dec;24(6):997-1003. doi: 10.1093/eurpub/ckt202. Epub 2013 Dec 23.

17.

Identifying patients with chronic conditions using pharmacy data in Switzerland: an updated mapping approach to the classification of medications.

Huber CA, Szucs TD, Rapold R, Reich O.

BMC Public Health. 2013 Oct 30;13:1030. doi: 10.1186/1471-2458-13-1030.

18.

Polypharmacy and potentially inappropriate medication in the adult, community-dwelling population in Switzerland.

Blozik E, Rapold R, von Overbeck J, Reich O.

Drugs Aging. 2013 Jul;30(7):561-8. doi: 10.1007/s40266-013-0073-0.

PMID:
23553511
19.

Fas activates lipolysis in a Ca2+-CaMKII-dependent manner in 3T3-L1 adipocytes.

Rapold RA, Wueest S, Knoepfel A, Schoenle EJ, Konrad D.

J Lipid Res. 2013 Jan;54(1):63-70. doi: 10.1194/jlr.M028035. Epub 2012 Oct 21.

20.

An empirical investigation of the efficiency effects of integrated care models in Switzerland.

Reich O, Rapold R, Flatscher-Thöni M.

Int J Integr Care. 2012 Jan-Mar;12:e2. Epub 2012 Jan 13.

21.

Efficient generation of multipotent mesenchymal stem cells from umbilical cord blood in stroma-free liquid culture.

Peters R, Wolf MJ, van den Broek M, Nuvolone M, Dannenmann S, Stieger B, Rapold R, Konrad D, Rubin A, Bertino JR, Aguzzi A, Heikenwalder M, Knuth AK.

PLoS One. 2010 Dec 30;5(12):e15689. doi: 10.1371/journal.pone.0015689.

22.

Fas activation in adipocytes impairs insulin-stimulated glucose uptake by reducing Akt.

Wueest S, Rapold RA, Schoenle EJ, Konrad D.

FEBS Lett. 2010 Oct 8;584(19):4187-92. doi: 10.1016/j.febslet.2010.08.052. Epub 2010 Sep 7.

23.

Deletion of Fas in adipocytes relieves adipose tissue inflammation and hepatic manifestations of obesity in mice.

Wueest S, Rapold RA, Schumann DM, Rytka JM, Schildknecht A, Nov O, Chervonsky AV, Rudich A, Schoenle EJ, Donath MY, Konrad D.

J Clin Invest. 2010 Jan;120(1):191-202. doi: 10.1172/JCI38388. Epub 2009 Dec 1.

24.

Basal lipolysis, not the degree of insulin resistance, differentiates large from small isolated adipocytes in high-fat fed mice.

Wueest S, Rapold RA, Rytka JM, Schoenle EJ, Konrad D.

Diabetologia. 2009 Mar;52(3):541-6. doi: 10.1007/s00125-008-1223-5. Epub 2008 Dec 2.

PMID:
19048227

Supplemental Content

Loading ...
Support Center